转化肺癌研究 SCIE

期刊简介预计审稿时间： In-house review: 1-3 weeks; External peer review: 1-3 months; Publication Ahead of Print: within 1 month after being accepted

Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.

转化肺癌研究（TLCR，Transl Lung Cancer Res，印刷 ISSN 2218-6751；在线 ISSN 2226-4477）是一本国际性、同行评审、开放获取期刊，创刊于 2012 年 3 月。TLCR 被 PubMed/PubMed Central 和化学文摘服务 (CAS) 数据库收录。该期刊第一年每季度出版一次，自 2013 年 2 月起每两个月出版一次。它提供有关肺癌预防、早期检测、诊断和治疗的实用最新信息。其关注的特定领域包括但不限于多模态治疗、标记物、成像、肿瘤生物学、病理学、化学预防和与肺癌相关的技术进步。

《Translational Lung Cancer Research》(转化肺癌研究)编辑部通讯方式为Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China.。如果您需要协助投稿或润稿服务，您可以咨询我们的客服老师。我们专注于期刊投稿服务十年，熟悉发表政策，可为您提供一对一投稿指导，避免您在投稿时频繁碰壁，节省您的宝贵时间，有效提升发表机率，确保SCI检索（检索不了全额退款）。我们视信誉为生命，多方面确保文章安全保密，在任何情况下都不会泄露您的个人信息或稿件内容。